Compare Recursion Pharmaceuticals Inc (RXRX) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.31B), while Virgin Galactic Holdings, Inc. trades at $2.94 (market cap $456.30M). The key difference: Recursion Pharmaceuticals Inc is far larger — about 5.1× Virgin Galactic Holdings, Inc.'s market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| RXRX | SPCE | |
|---|---|---|
Market Cap | $2.31B | $456.30M |
Volume | 40,478,768 | 4,518,834 |
Sector | Health | Industrials |
52-Week High | $6.79 | $7.52 |
52-Week Low | $2.84 | $2.17 |
Typical Hold Time | 22 Days | 69 Days |
Enterprise Value | $1.83B | $420.29M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
SPCE trades at $2.94, down 4.23% today, reflecting a bearish technical outlook amid persistent fundamental challenges. The company continues to report significant losses, with a net income margin of -23,867.44% in 2025, though recent quarters have seen earnings beats. Cash flow remains negative, but trends show improvement, with a projected positive net cash flow of $25M in 2026. Analyst sentiment is mixed, with a Buy/Hold/Sell split of 29%/41%/29%.
The outlook remains high-risk due to ongoing cash burn and delayed commercial flights, but strong ticket demand and a path to positive cash flow by 2027 offer long-term potential. Investors face substantial volatility and dilution risks, requiring careful risk management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
